RAPID MICRO BIOSYSTEMS INC-A Business Summary

Rapid Micro Biosystems Inc. (RPID) operates a high-margin "razor-and-blade" business model centered on its flagship Growth Direct platform, which automates microbial quality control (MQC) testing for pharmaceutical manufacturing. The company generates revenue through three primary segments: Systems (capital equipment sales of automated imaging instruments), Consumables (recurring sales of proprietary testing plates), and Services (validation, maintenance, and LIMS software integration). By reducing testing incubation periods from 14 days to as little as 1–3 days, the company provides mission-critical efficiency for manufacturers of biologics, vaccines, and cell therapies. RPID competes directly with legacy manual testing providers and automated solution firms such as Charles River Laboratories, bioMérieux, and Cytek Biosciences, positioning itself as a premium, specialized automation leader for high-complexity sterile manufacturing environments. Founded in 2006 by Donald Straus, the company is led by President and CEO Robert G. Spignesi Jr., who brings extensive pedigree from senior roles at Thermo Fisher Scientific and McKesson. The executive team includes CFO Sean Wirtjes, formerly of Boston Scientific and Varian, COO John Wilson, who held leadership positions at Medtronic and Becton Dickinson, and VP of R&D Todd Ballantyne, a veteran of DEKA R&D and Medtronic. The company is supported by a high-profile Board of Directors, including Chairman Kirk D. Malloy and Dafni Bika (SVP at AstraZeneca), and maintains a strong institutional investor base featuring BlackRock, Vanguard, and Ally Bridge Group. Recent strategic momentum is underscored by a global distribution partnership with MilliporeSigma, aimed at accelerating the adoption of its automated MQC technology across international markets.